Di Lorenzo G - Search Results

1

Kidney cancer: overall survival is an unsuitable primary end point.

Di Lorenzo G, Buonerba C. Di Lorenzo G, et al. Nat Rev Urol. 2010 Jul;7(7):367-8. doi: 10.1038/nrurol.2010.84. Nat Rev Urol. 2010. PMID: 20616795

2

Ten-year adjuvant treatment with somatostatin analogs in a patient with atypical carcinoid of the lung.

Buonerba C, Gallo C, Di Lorenzo G, Romeo V, Marinelli A. Buonerba C, et al. Among authors: di lorenzo g. Anticancer Drugs. 2010 Apr;21(4):465-8. doi: 10.1097/CAD.0b013e32833688a2. Anticancer Drugs. 2010. PMID: 20075713

3

Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer.

Riccardi F, Di Lorenzo G, Buonerba C, Monaco G, Monaco R, Rizzo M, Scagliarini S, Scognamiglio F, Di Napoli M, Carteni' G. Riccardi F, et al. Among authors: di lorenzo g, di napoli m. World J Surg Oncol. 2010 Feb 5;8:8. doi: 10.1186/1477-7819-8-8. World J Surg Oncol. 2010. PMID: 20137082 Free PMC article.

4

Castration-resistant prostate cancer: current and emerging treatment strategies.

Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Sternberg CN. Di Lorenzo G, et al. Drugs. 2010 May 28;70(8):983-1000. doi: 10.2165/10898600-000000000-00000. Drugs. 2010. PMID: 20481655 Review.

5

Efficacy of rituximab in gastric diffuse large B cell lymphoma patients.

Leopardo D, Di Lorenzo G, De Renzo A, Federico P, Luponio S, Buonerba C, Matano E, Merola G, Imbimbo M, Montesarchio E, Rea A, Merola MC, De Placido S, Palmieri G. Leopardo D, et al. Among authors: di lorenzo g. World J Gastroenterol. 2010 May 28;16(20):2526-30. doi: 10.3748/wjg.v16.i20.2526. World J Gastroenterol. 2010. PMID: 20503452 Free PMC article.

6

Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?

Gallo C, Buonerba C, Di Lorenzo G, Romeo V, De Placido S, Marinelli A. Gallo C, et al. Among authors: di lorenzo g. J Neurooncol. 2010 Nov;100(2):311-9. doi: 10.1007/s11060-010-0168-y. Epub 2010 Jun 17. J Neurooncol. 2010. PMID: 20556481

7

Docetaxel rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice.

Buonerba C, Palmieri G, Di Lorenzo G. Buonerba C, et al. Among authors: di lorenzo g. Eur Urol. 2010 Oct;58(4):636-7. doi: 10.1016/j.eururo.2010.06.025. Epub 2010 Jun 23. Eur Urol. 2010. PMID: 20580484 No abstract available.

8

Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer.

Di Lorenzo G, Buonerba C, Faiella A, Rescigno P, Rizzo M, Autorino R, Perdonà S, Riccardi N, Scagliorini S, Scognamiglio F, Masala D, Ferro M, Palmieri G, Aieta M, Marinelli A, Altieri V, De Placido S, Cartenì G. Di Lorenzo G, et al. BJU Int. 2011 Jan;107(2):234-9. doi: 10.1111/j.1464-410X.2010.09498.x. BJU Int. 2011. PMID: 20590545 Clinical Trial.

9

Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.

Di Lorenzo G, Buonerba C, Federico P, Rescigno P, Milella M, Ortega C, Aieta M, D'Aniello C, Longo N, Felici A, Ruggeri EM, Palmieri G, Imbimbo C, Aglietta M, De Placido S, Mirone V. Di Lorenzo G, et al. Eur Urol. 2010 Dec;58(6):906-11. doi: 10.1016/j.eururo.2010.09.008. Epub 2010 Sep 24. Eur Urol. 2010. PMID: 20884115

10

A comprehensive outlook on intracerebral therapy of malignant gliomas.

Buonerba C, Di Lorenzo G, Marinelli A, Federico P, Palmieri G, Imbimbo M, Conti P, Peluso G, De Placido S, Sampson JH. Buonerba C, et al. Among authors: di lorenzo g. Crit Rev Oncol Hematol. 2011 Oct;80(1):54-68. doi: 10.1016/j.critrevonc.2010.09.001. Epub 2010 Oct 2. Crit Rev Oncol Hematol. 2011. PMID: 20888252 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

783 results

Search Page

Filters